期刊
NATURE REVIEWS DISEASE PRIMERS
卷 1, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrdp.2015.56
关键词
-
资金
- Eli Lilly
- Roche
- Merck
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Amgen)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Biogen Idec)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Eisai)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (FORUM)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Genentech)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Janssen)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Lilly)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Roche)
- Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (Sanofi)
- GE Healthcare
- Avid Radiopharmaceuticals
- Primal
- AstraZeneca
- Navidea
- Janssen
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%. Most patients with Alzheimer's disease (>95%) have the sporadic form, which is characterized by a late onset (80-90 years of age), and is the consequence of the failure to clear the amyloid-beta (A beta) peptide from the interstices of the brain. A large number of genetic risk factors for sporadic disease have been identified. A small proportion of patients (<1%) have inherited mutations in genes that affect processing of A beta and develop the disease at a much younger age (mean age of similar to 45 years). Detection of the accumulation of A beta is now possible in preclinical and prodromal phases using cerebrospinal fluid biomarkers and PET. Several approved drugs ameliorate some of the symptoms of Alzheimer's disease, but no current interventions can modify the underlying disease mechanisms. Management is focused on the support of the social networks surrounding the patient and the treatment of any co-morbid illnesses, such as cerebrovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据